The 2 Best Stocks Under $5 to Buy Right Now: AQST & CLOV
With the stock market filled with volatile opportunities, investors on a budget often search for promising stocks under $5. Two stocks currently making waves are Aquestive Therapeutics, Inc. (AQST) and Clover Health Investments, Corp. (CLOV). Both companies have seen recent rallies and have exciting upcoming catalysts that could continue their upward momentum. Let’s dive into why these two stocks stand out.
1. Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics is a pharmaceutical company that focuses on developing and commercializing treatments to solve patients’ critical needs. AQST recently experienced a notable rally, seeing gains driven by increased investor confidence in its portfolio of orally administered therapies. The stock is priced attractively under $5 and has been climbing due to its potential catalysts.
Upcoming Catalysts:
FDA Approval:One of the biggest potential drivers for AQST is the pending FDA decision on its key product Libervant, a treatment for seizures. If the FDA grants approval, it could propel the stock even higher.
Partnership Opportunities: AQST has ongoing discussions about potential collaborations, which could strengthen its market position and boost investor confidence.
Q3 Earnings Report: Expected in early November 2024, AQST’s earnings will be crucial in determining whether it can maintain its momentum. Investors will be watching for updates on Libervant and other pipeline products.
2. Clover Health Investments, Corp. (CLOV)
Clover Health, a Medicare Advantage insurer, is another budget-friendly stock under $5 that has caught investors’ attention. CLOV saw a significant rally earlier in 2024 after a better-than-expected earnings report and has managed to sustain investor interest due to its commitment to improving healthcare efficiency with technology.
Recent Rally and Upcoming Catalysts:
Q2 Earnings Beat: In August 2024, Clover Health surprised investors by reporting earnings of $0.01 per share, beating analysts’ expectations of a -$0.04 loss. This earnings beat, along with a 11% revenue growth year-over-year, triggered a surge in its stock price【23†source】【24†source】.
- Q3 Earnings Report: Clover Health’s next earnings report is expected on November 4, 2024, and with strong recent performance, analysts expect another potential beat, which could continue driving the stock higher.
AI-Powered Partnerships: Clover is leveraging AI through partnerships like the Counterpart Health deal announced in September 2024, which aims to enhance healthcare delivery across the Midwest【24†source】. These partnerships could provide significant long-term growth potential for the company.
Conclusion:
AQST and CLOV are two stocks under $5 that present high upside potential for risk-tolerant investors. With pending FDA decisions, earnings reports, and innovative partnerships, both companies have key catalysts that could lead to further rallies in the coming months. For those looking to capitalize on the next big stock under $5, AQST and CLOV are worth serious consideration.
